Arecor
arecor.com
Actively hiring
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$6.5M
1 round on record
Latest round
$6.5M
Venture round · Sep 2026 · this month
Backers
1
Albion
The money's age
Fresh money
0 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 28
Raised a round Venture round $6.5M
2015
Founded
Nov 10, 2011
New executive Arecor Appoints Dr. Sarah Howell as Chief Operating Officer · PRNewswire
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2026 | $6.5M | — | businessweekly.co.uk |
Backed byfrom the funds' portfolios and accelerator catalogs
Albion Investors in similar startupsfunds that back the companies most like this one
backs Goodpath
Similar startupsby what they do, their industry and backers
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular…
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related…
Long-Acting Medicines to Transform Metabolic Health. Pioneering long-acting antibody conjugates to deliver quarterly administered…
Clinicient’s Insight Platform streamlines operations and improves outcomes for PT, OT, and SLP organizations of all sizes.
Cyrus Bio is a computationally-driven discovery company focused on naturally existing proteins that show the potential to be turned into…
News
Interim results for the six months to 30 June 2026
The post Interim results for the six months to 30 June 2026 appeared first on Arecor.
Read more
Report
Proposed Fundraising to raise up to £5.13 million
The post Proposed Fundraising to raise up to £5.13 million appeared first on Arecor.
Read more
Report
HCP Live: Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI
The post HCP Live: Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI appeared first on Arecor.
Read more
Report
Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies Clarivate
Discover seven emerging companies advancing next-generation obesity therapies. Explore innovations in oral treatments, muscle-preserving approaches and novel mechanisms beyond GLP-1s in Clarivate's latest Companies to Watch report.
Read more
Report
Peer-Reviewed Publication of AT278 Study in Diabetes, Obesity and Metabolism journal
The post Peer-Reviewed Publication of AT278 Study in Diabetes, Obesity and Metabolism journal appeared first on Arecor.
Read more
Report
Clarivate report - Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies
The post Clarivate report - Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies appeared first on Arecor.
Read more
Report
Diabetes, Obesity and Metabolism article A New Highly Concentrated Insulin Aspart AT278 (500 UmL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI 30 July 2026
Read more
Report
Diabetes, Obesity and Metabolism article - A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI
The post Diabetes, Obesity and Metabolism article - A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI appeared first on Arecor.
Read more
Report
Show more news
Financials
Total raised
$6.5M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $6.5M | Details |